Valuation: Omeros Corporation

Market Cap 1.39B 1.23B 1.16B 1.06B 1.98B 134B 2B 13.96B 5.38B 68.28B 5.23B 5.12B 220B P/E 2026 *
21.2x
P/E 2027 * 18.2x
Enterprise Value 1.39B 1.23B 1.16B 1.06B 1.98B 134B 2B 13.96B 5.38B 68.28B 5.23B 5.12B 220B EV / Sales 2026 *
10.9x
EV / Sales 2027 * 6.3x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.93%
1 week-8.55%
Current month+2.45%
1 month+3.44%
3 months+94.25%
6 months+94.84%
Current year+12.08%
1 week 19
Extreme 19
20.62
1 month 16.5
Extreme 16.5001
21.24
Current year 6.7
Extreme 6.7023
21.24
1 year 4.06
Extreme 4.055
21.24
3 years 0.92
Extreme 0.92
21.24
5 years 0.92
Extreme 0.92
21.24
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/23/26 Exercice

Chief Financial Officer

30,000 0.0414%
8/31/26 Exercice

General Counsel

75,000 0.1036%
8/27/26 Exercice

Director

30,000 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%-8.55%+360.53%+559.25% 1.41B
-0.70%-4.35%+56.10%+86.42% 71.81B
+0.45%-0.82%+38.81%+84.19% 60.06B
+0.19%+0.94%+36.97%+21.32% 27.93B
-1.73%-4.30%-18.37%+357.94% 25.7B
-0.51%-2.28%+0.48%-9.27% 24.89B
+0.65%+2.52%+25.89%-6.99% 20.92B
+3.46%+3.91%+158.90%+337.81% 15.04B
+0.48%+0.86%+44.56%+168.42% 14.46B
+3.91%-4.56%-2.71%+506.41% 13.87B
Average +0.53%-0.32%+70.12%+210.55% 27.61B
Weighted average by Cap. +0.18%-1.71%+39.76%+130.42%

Financials

2026 *2027 *
Net sales 128M 113M 106M 96.55M 181M 12.23B 183M 1.28B 492M 6.25B 479M 468M 20.1B 221M 195M 185M 168M 314M 21.24B 317M 2.22B 854M 10.84B 831M 813M 34.9B
Net income 64.97M 57.33M 54.25M 49.2M 92.23M 6.23B 93.14M 651M 251M 3.18B 244M 239M 10.24B 84.8M 74.84M 70.81M 64.21M 120M 8.14B 122M 849M 327M 4.16B 318M 311M 13.37B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-09-29 US$19.25 -0.93% 841,695
26-09-28 US$19.43 -3.24% 1,026,395
26-09-25 US$20.08 -0.25% 942,084
26-09-24 US$20.13 -2.94% 909,690
26-09-23 US$20.74 -1.47% 1,349,574
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.25USD
Average target price
27.50USD
Spread / Average Target
+42.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock